We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The rise of COVID-19 represents an unprecedented situation for pharma. With the scramble to find a vaccine, R&D productivity is more important than ever, which makes it especially concerning that pharma still struggles with a widely recognized productivit
Returns on pharma R&D investment are at a nine-year low, and the cost of developing a drug has nearly doubled since 2010, according to Deloitte’s yearly assessment of the industry’s pipeline productivity.